Relationship between menopausal hormone therapy and incidence of fractures in postmenopausal women

References

• Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359(9319):1761–1767. doi: 10.1016/S0140-6736(02)08657-9.
   PubMed Web of Science ®Google Scholar
• Sowers MR, Zheng H, Greendale GA, et al. Changes in bone resorption across the menopause transition: effects of reproductive hormones, body size, and ethnicity. J Clin Endocrinol Metab. 2013;98(7):2854–2863. doi: 10.1210/jc.2012-4113.
   PubMed Web of Science ®Google Scholar
• Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2014;142:155–170. doi: 10.1016/j.jsbmb.2013.09.008.
   PubMed Web of Science ®Google Scholar
• Gambacciani M, et al. Longitudinal evaluation of perimenopausal vertebral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism. Obstet Gynecol. 1994;83(3):392–396.
   PubMed Web of Science ®Google Scholar
• Wells G, Tugwell P, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev. 2002;23(4):529–539. doi: 10.1210/er.2001-5002.
   PubMed Web of Science ®Google Scholar
• Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA. 1996;276(17):1389–1396.
   PubMed Web of Science ®Google Scholar
• Lindsay R, Bush TL, Grady D, et al. Therapeutic controversy: estrogen replacement in menopause. J Clin Endocrinol Metab. 1996;81(11):3829–3838. doi: 10.1210/jc.81.11.3829.
   PubMed Web of Science ®Google Scholar
• Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials. BMC Musculoskelet Disord. 2001;2(1):7. doi: 10.1186/1471-2474-2-7.
   PubMedGoogle Scholar
• Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study. JAMA. 1997;277(7):543–547. doi: 10.1001/jama.1997.03540310041032.
   PubMed Web of Science ®Google Scholar
• Weiss NS, Ure CL, Ballard JH, et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med. 1980;303(21):1195–1198. doi: 10.1056/NEJM198011203032102.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
   PubMed Web of Science ®Google Scholar
• Anderson GL, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–1712.
   PubMed Web of Science ®Google Scholar
• Pasco JA, Kotowicz MA, Henry MJ, et al. Hormone therapy and risk of non-vertebral fracture: Geelong osteoporosis study. Osteoporos Int. 2004;15(6):434–438. doi: 10.1007/s00198-003-1574-1.
   PubMed Web of Science ®Google Scholar
• Bjarnason NH, Christiansen C. Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone. 2000;26(6):561–569. doi: 10.1016/s8756-3282(00)00272-6.
   PubMed Web of Science ®Google Scholar
• Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer’s Disease Cooperative Study. JAMA. 2000;283(8):1007–1015. doi: 10.1001/jama.283.8.1007.
   PubMed Web of Science ®Google Scholar
• Orr-Walker BJ, Evans MC, Clearwater JM, et al. Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women. Arch Intern Med. 2000;160(14):2161–2166. doi: 10.1001/archinte.160.14.2161.
   PubMedGoogle Scholar
• Recker RR, Davies KM, Dowd RM, et al. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial. Ann Intern Med. 1999;130(11):897–904. doi: 10.7326/0003-4819-130-11-199906010-00005.
   PubMed Web of Science ®Google Scholar
• Weiss SR, Ellman H, Dolker M. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Obstet Gynecol. 1999;94(3):330–336. doi: 10.1097/00006250-199909000-00002.
   PubMed Web of Science ®Google Scholar
• Khosla S, Oursler MJ, Monroe DG. Estrogen and the skeleton. Trends Endocrinol Metab. 2012;23(11):576–581. doi: 10.1016/j.tem.2012.03.008.
   PubMed Web of Science ®Google Scholar
• Prior JC. Progesterone or progestin as menopausal ovarian hormone therapy: recent physiology-based clinical evidence. Curr Opin Endocrinol Diabetes Obes. 2015;22(6):495–501. doi: 10.1097/MED.0000000000000205.
   PubMedGoogle Scholar
• Verhaar HJ, Damen CA, Duursma SA, et al. A comparison of the action of progestins and estrogen on the growth and differentiation of normal adult human osteoblast-like cells in vitro. Bone. 1994;15(3):307–311. doi: 10.1016/8756-3282(94)90293-3.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008;359(7):697–708. doi: 10.1056/NEJMoa0800743.
   PubMed Web of Science ®Google Scholar
• Cummings SR. A 55-year-old woman with osteopenia. JAMA. 2006;296(21):2601–2610. doi: 10.1001/jama.296.21.2601.
   PubMed Web of Science ®Google Scholar
• Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA. 2003;290(13):1729–1738. doi: 10.1001/jama.290.13.1729.
   PubMed Web of Science ®Google Scholar
• Baek JK, Kim HI, Kang MJ, et al. Relationship between the type of hormone replacement therapy and incidence of breast cancer in Korea. Climacteric. 2022;25(5):516–522. doi: 10.1080/13697137.2022.2077096.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi: 10.1016/0021-9681(87)90171-8.
   PubMedGoogle Scholar
• Rozenberg S, Al-Daghri N, Aubertin-Leheudre M, et al. Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis? Osteoporos Int. 2020;31(12):2271–2286. doi: 10.1007/s00198-020-05497-8.
   PubMed Web of Science ®Google Scholar
• Gosset A, Pouilles JM, Tremollieres F. Menopausal hormone therapy for the management of osteoporosis. Best Pract Res Clin Endocrinol Metab. 2021;35(6):101551. doi: 10.1016/j.beem.2021.101551.
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Stevenson JC. The WHI: the effect of hormone replacement therapy on fracture prevention. Climacteric. 2012;15(3):263–266. doi: 10.3109/13697137.2012.659975.
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605–613. doi: 10.1001/jama.280.7.605.
   PubMed Web of Science ®Google Scholar
• Cauley JA, Black DM, Barrett-Connor E, et al. Effects of hormone replacement therapy on clinical fractures and height loss: the Heart and Estrogen/Progestin Replacement Study (HERS). Am J Med. 2001;110(6):442–450. doi: 10.1016/s0002-9343(01)00647-7.
   PubMed Web of Science ®Google Scholar
• Richman S, Edusa V, Fadiel A, et al. Low-dose estrogen therapy for prevention of osteoporosis: working our way back to monotherapy. Menopause. 2006;13(1):148–155. doi: 10.1097/01.gme.0000191205.20738.01.
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kleerekoper M, et al. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 2002;287(20):2668–2676. doi: 10.1001/jama.287.20.2668.
   PubMed Web of Science ®Google Scholar
• Prestwood KM, Kenny AM, Kleppinger A, et al. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA. 2003;290(8):1042–1048. doi: 10.1001/jama.290.8.1042.
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kleerekoper M, et al. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporos Int. 2005;16(4):372–379. doi: 10.1007/s00198-004-1773-4.
   PubMed Web of Science ®Google Scholar
• Leung KY, et al. The effects of different dosages of oestrogen on the bone mineral density of postmenopausal Hong Kong Chinese women: randomised controlled trial. Hong Kong Med J. 1999;5(1):9–14.
   PubMedGoogle Scholar
• Kyvernitakis I, Kostev K, Hars O, et al. Discontinuation rates of menopausal hormone therapy among postmenopausal women in the post-WHI study era. Climacteric. 2015;18(5):737–742. doi: 10.3109/13697137.2015.1037267.
   PubMed Web of Science ®Google Scholar
• Kim MK, Jung YS, Chon SJ, et al. Common causes of postmenopausal bleeding in Korean women: 10-year outcomes from a single medical center. J Korean Med Sci. 2017;32(5):830–834. doi: 10.3346/jkms.2017.32.5.830.
   PubMed Web of Science ®Google Scholar
• Yates J, Barrett-Connor E, Barlas S, et al. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol. 2004;103(3):440–446. doi: 10.1097/01.AOG.0000114986.14806.37.
   PubMed Web of Science ®Google Scholar
• Engel P, Fabre A, Fournier A, et al. Risk of osteoporotic fractures after discontinuation of menopausal hormone therapy: results from the E3N cohort. Am J Epidemiol. 2011;174(1):12–21. doi: 10.1093/aje/kwr044.
   PubMed Web of Science ®Google Scholar
• Karim R, Dell RM, Greene DF, et al. Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause. 2011;18(11):1172–1177. doi: 10.1097/gme.0b013e31821b01c7.
   PubMed Web of Science ®Google Scholar
• Liu L, et al. 17beta-estradiol attenuates ovariectomyinduced bone deterioration through the suppression of the ephA2/ephrinA2 signaling pathway. Mol Med Rep. 2018;17(1):1609–1616.
   PubMed Web of Science ®Google Scholar
• Terzi H, Cırpan T, Terzi R, et al. Osteoprotective effect of hormone therapy on bone microarchitecture before impaired bone mineral density in ovariectomized rats. J Turk Ger Gynecol Assoc. 2012;13(4):261–266. doi: 10.5152/jtgga.2012.42.
   PubMedGoogle Scholar
• Liang M, Liao E-Y, Xu X, et al. Effects of progesterone and 18-methyl levonorgestrel on osteoblastic cells. Endocr Res. 2003;29(4):483–501. doi: 10.1081/erc-120026954.
   PubMed Web of Science ®Google Scholar
• Gavali S, Gupta MK, Daswani B, et al. LYN, a key mediator in estrogen-dependent suppression of osteoclast differentiation, survival, and function. Biochim Biophys Acta Mol Basis Dis. 2019;1865(3):547–557. doi: 10.1016/j.bbadis.2018.12.016.
   PubMed Web of Science ®Google Scholar
• Chen F, Ouyang Y, Ye T, et al. Estrogen inhibits RANKL-induced osteoclastic differentiation by increasing the expression of TRPV5 channel. J Cell Biochem. 2014;115(4):651–658. doi: 10.1002/jcb.24700.
   PubMed Web of Science ®Google Scholar
• Gallagher JC. Does tibolone reduce the risk of fracture in older postmenopausal women with osteoporosis? Nat Clin Pract Endocrinol Metab. 2009;5(3):128–129. doi: 10.1038/ncpendmet1063.
   PubMedGoogle Scholar
• Bundred NJ, Kenemans P, Yip CH, et al. Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy. Breast Cancer Res. 2012;14(1):R13. doi: 10.1186/bcr3097.
   PubMed Web of Science ®Google Scholar